Skip to main content
Log in

Impact of microarray data quality on genomic data submissions to the FDA

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

How can microarray data best be exploited and integrated into the regulatory decision-making process?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Increase in formal requests (consults) for genomic data review (data submitted as part of regular INDs, NDAs or BLAs) to the Office of Clinical Pharmacology, and voluntary genomic data submissions (VGDS) to the FDA, since 2004.

References

  1. International Human Genome Sequencing Consortium. Nature 409, 860–921 (2001).

  2. Venter, J.C. et al. Science 291, 1304–1351 (2001).

    Article  CAS  Google Scholar 

  3. Lesko, L.J. & Woodcock, J. Pharmacogenomics J. 2, 20–24 (2002).

    Article  CAS  Google Scholar 

  4. http://www.fda.gov/cder/guidance/6400fnl.pdf

  5. http://www.cfsan.fda.gov/∼dms/opa-pt58.html

  6. Shi, L. et al. Expert Rev. Mol. Diagn. 4, 761–777 (2004).

    Article  Google Scholar 

  7. Shi, L. et al. BMC Bioinformatics 6 suppl. Suppl. 2, S12 (2005).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frueh, F. Impact of microarray data quality on genomic data submissions to the FDA. Nat Biotechnol 24, 1105–1107 (2006). https://doi.org/10.1038/nbt0906-1105

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0906-1105

  • Springer Nature America, Inc.

This article is cited by

Navigation